Adam Schayowitz, Ph.D, MBA, is an Operating Partner at EcoR1 Capital LLC, a biotech-focused investment advisory firm which invests in companies at all stages of research and development.  With nearly 20 years of oncology drug development experience, Adam has led dozens of global development programs from initiation through approval and commercialization.

Prior to joining EcoR1, he was a Vice President at Pfizer Oncology with various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in the Head of Product Development Teams for Pfizer Oncology.  Prior to Pfizer, Adam led the development of Zejula (niraparib) at Tesaro and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo (Radium-223).  He is a Board Member at Scorpion Therapeutics, Terremoto Bio and serves as a Board Observer for Aktis Oncology.

Adam has a Bachelor of Arts from Hamilton College, a Ph.D in Pharmacology from The University of Maryland and an MBA from Johns Hopkins.